EFFICACY OF CHECKPOINT INHIBITOR IMMUNOTHERAPY DRUG PEMBROLIZUMAB (KEYTRUDA) FOR TREATMENT OF ADVANCED CERVICAL CANCER

被引：0
|
作者：
Ahmed, F. [1 ]
Shah, Z. [2 ]
Khan, I. [1 ]
Bhatnagar, A. [1 ]
Garimella, R. [1 ]
Mishra, S. [1 ]
Gudapati, S. [3 ]
Bobba, S. H. [3 ]
Zaidi, S. [4 ]
Andrews, K. [5 ]
Salman, U. [6 ]
Yukselen, Z. [1 ]
Guntipalli, P. [1 ]
Zarrar, R. [7 ]
Nya, G. Enebong [8 ]
Ahmad, S. [9 ]
机构：
[1] Larkin Community Hosp, Div Clin & Translat Res, South Miami, FL USA
[2] Weiss Mem Hosp, Dept Internal Med, Chicago, IL USA
[3] Washington Univ Hlth & Sci, Coll Med, San Pedro, Belize
[4] Lahore Med & Dent Coll, Coll Med, Lahore, Pakistan
[5] Prince Mohammad Bin Fahad Univ, Dept CORE, Al Khobar, Saudi Arabia
[6] Bakhtawar Amin Med & Dent Coll, Coll Med, Multan, Pakistan
[7] Mayo Clin, Dept Oncol, Rochester, MN USA
[8] Johns Hopkins Univ Hosp, Dept Gynecol Oncol, Baltimore, MD USA
[9] Advent Hlth Canc Inst, Div Gynecol Oncol, Orlando, FL USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷
关键词：
D O I：
10.1136/ijgc-2021-ESGO.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
567
引用
收藏
页码：A32 / A32
页数：1
相关论文
共 50 条
  • [1] SAFETY PROFILE OF KEYTRUDA (PEMBROLIZUMAB) FOR THE TREATMENT OF PATIENTS WITH ADVANCED PD-L1 POSITIVE CERVICAL CANCER
    Ahmed, F.
    Khan, I.
    Shah, Z.
    Garimella, R.
    Mishra, S.
    Bhatnagar, A.
    Andrews, K.
    Zaidi, S.
    Salman, U.
    Bobba, S. H.
    Gudapati, S.
    Yukselen, Z.
    Guntipalli, P.
    Michel, J.
    Ahmad, S.
    Zarrar, R.
    Nya, G. Enebong
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A42 - A43
  • [2] Clinical Outcomes and Molecular Predictors of Pembrolizumab (Keytruda) as a PD-1 Immune Checkpoint Inhibitor in Advanced and Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis
    Balan, Lavinia
    Cimpean, Anca Maria
    Nandarge, Prashant Sunil
    Sorop, Bogdan
    Balan, Catalin
    Balica, Madalina Alexandra
    Bratosin, Felix
    Brasoveanu, Simona
    Boruga, Madalina
    Pirtea, Laurentiu
    BIOMEDICINES, 2024, 12 (05)
  • [3] Pembrolizumab for advanced cervical cancer: safety and efficacy
    De Felice, Francesca
    Giudice, Elena
    Bolomini, Giulia
    Distefano, Maria Grazia
    Scambia, Giovanni
    Fagotti, Anna
    Marchetti, Claudia
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (02) : 221 - 228
  • [4] Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study
    Shieh, Kevin R.
    Huang, Anna
    Xu, Yiqing
    FRONTIERS IN MEDICINE, 2021, 8
  • [5] The efficacy and safety of pembrolizumab in advanced cervical cancer: A real-world treatment study
    Browne, I.
    Chew, S.
    Fennelly, D.
    Crown, J.
    Murray, H.
    Rahman, R.
    McCaffrey, J.
    Kelly, C.
    Osman, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S1438 - S1439
  • [6] Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer
    Zhang, Xue
    Yin, Wen-Jie
    Zhang, Ai-Li
    Zhang, Xiao-Xiao
    Ding, Li-Juan
    Zhang, Jiao
    He, Shu-Ting
    Yan, Jie-Ping
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2024, 44 (01)
  • [7] Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study
    Malek, Alexandre E.
    Khalil, Melissa
    Hachem, Ray
    Chaftari, Anne Marie
    Fares, Johny
    Jiang, Ying
    Kontoyiannis, Dimitrios P.
    Fossella, Frank
    Chaftari, Patrick
    Mulanovich, Victor E.
    Viola, George M.
    Raad, Issam I.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) : E2697 - E2704
  • [8] Immunotherapy with Checkpoint Inhibitor Pembrolizumab New Long-term Data for Patients with advanced malignant Melanoma
    Schoellmann, Claudia
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (10) : 671 - 671
  • [9] Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients
    B. Fox
    M. de Toro Carmena
    R. Álvarez Álvarez
    A. Calles Blanco
    C. López López
    S. Pérez Ramírez
    J. Á. Arranz
    M. Martín
    I. Márquez-Rodas
    Clinical and Translational Oncology, 2020, 22 : 555 - 562
  • [10] Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients
    Fox, B.
    de Toro Carmena, M.
    Alvarez Alvarez, R.
    Calles Blanco, A.
    Lopez Lopez, C.
    Perez Ramirez, S.
    Arranz, J. A.
    Martin, M.
    Marquez-Rodas, I
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (04): : 555 - 562
12345